Nantes, France, April 19, 2011 – TcLand Expression, a leading company focused on gene expression biomarkers in immunology and personalized medicine today announced the appointment of Felix Frueh PhD, as new member of the company’s Board of Directors.
“We are particularly honored that a personality like Felix Frueh has agreed to join TcLand Expression’s Board of Directors. Felix is one of the rare worldwide pioneers in personalized medicine and was instrumental for the development of such discipline during his time at the FDA. He now holds a key role in Medco, making personalized medicine and companion diagnostics a reality in medical practice. His vision and in-depth understanding of the market opportunities will highly benefit TcLand Expression and will be fundamental for achieving our next development milestones”, emphasized Alain Huriez, co-founder and Chief Executive Officer of the company.
“I am delighted to have been appointed as a member of the Board of TcLand. I am impressed by the scientific excellence of the company and its pioneering developments in the field of companion diagnostics. The company has all attributes of a worldwide leader in the development of algorithms critical for treatment decisions in therapeutic areas such as Rheumatoid Arthritis”, stated Felix Frueh. “TcLand Expression is well positioned to have a major, significant and quantifiable impact on patients’ needs in the field of personalized medicine”, he concluded.
Felix Frueh is President of Medco Research Institute®, a division of Medco, the largest US Pharmacy Benefit Manager. In this function, Felix Frueh manages Medco’s expanding peer-reviewed research initiatives and collaborations in personalized medicine, comparative effectiveness research and clinical practice improvements, leveraging the newest developments in science to improve the safety and efficacy of prescription drug care. He is also responsible for the development of Medco’s Personalized Medicine Research Center, which is under construction in Whitestown, Indiana. Felix joined Medco in May 2008 to lead the company’s personalized medicine research and development organization.
Prior to joining Medco, Felix Frueh was Associate Director for Genomics at the U.S. Food and Drug Administration (FDA), where he built and led the core genomics review team in the Center for Drug Evaluation and Research (CDER), and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG). Prior to the FDA, he was Managing Partner at Stepoutside Consulting, LLC, and held senior positions at Transgenomic and Protogene Laboratories. Felix Frueh has published numerous peer-reviewed articles and is a frequent invited speaker at national and international conferences. He has been a member of various working groups on genetics and genomics at the FDA and at the Department of Health and Human Services (DHHS), and is a Member of the Board of the Personalized Medicine Coalition. His academic career includes a faculty appointment at the Departments of Pharmacology and Medicine at Georgetown University in Washington DC, and postdoctoral fellowships at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry.
About TcLand Expression
TcLand Expression is a recognized pioneer in the discovery, development and validation of gene expression biomarkers for unmet medical needs in immunology. The company benefits from an exceptional scientific and clinical environment. For more information, please visit our website: www.tcland-expression.com
Contacts
Alain Huriez, CEO
TcLand Expression
Phone: +33 2 40 35 89 99
ahuriez@tcland-expression.com
Caroline Carmagnol
ALIZE RP
+ 33 6 64 18 99 59
caroline@alizerp.com
Anne-Sophie Cosquéric
33 1 42 68 86 41
anne-sophie@alizerp.com
